The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 22 February 2005, www.theannals.com, DOI 10.1345/aph.1E365.
 The Annals of Pharmacotherapy: Vol. 39, No. 4, pp. 732-735. DOI 10.1345/aph.1E365
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villeneuve, E.
Right arrow Articles by Sunderji, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villeneuve, E.
Right arrow Articles by Sunderji, R.

DRUG INFORMATION ROUNDS

Glycoprotein IIb/IIIa Inhibitors in Patients with End-Stage Renal Disease

Eric Villeneuve, MSc, PharmD

Student, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

Rubina Sunderji, PharmD FCSHP

Clinical Professor, Faculty of Pharmaceutical Sciences, University of British Columbia; Pharmacotherapy Specialist–Cardiology, Pharmaceutical Sciences CSU, Vancouver General Hospital, Vancouver

Reprints: Dr. Sunderji, Pharmaceutical Sciences CSU, Vancouver General Hospital, 855 W. 12th Ave., Vancouver, BC V5Z 1M9, Canada, fax 604/875-5267, rsunderj{at}vanhosp.bc.ca

OBJECTIVE: To determine whether glycoprotein IIb/IIIa inhibitors (GPIs) are effective and safe as adjunctive therapy for percutaneous coronary intervention (PCI) in patients with end-stage renal disease (ESRD).

DATA SOURCES: MEDLINE (1966–June 2004), EMBASE (1980–June 2004), and International Pharmaceutical Abstracts (1970–June 2004) were searched, in addition to a manual bibliographic search.

DATA SYNTHESIS: Even though GPIs have an established role as adjunctive therapy in PCI, little is known about their use in patients with ESRD. We found 3 reports describing experience with abciximab in this population. Based on the limited information from registries and a retrospective chart review, it is difficult to draw definitive conclusions about the utility of GPIs in ESRD. The decision to use abciximab in this population must be made on an individual case basis.

CONCLUSIONS: Studies are needed to evaluate the benefit versus risk of GPI therapy in ESRD.

Key Words: dialysis, end-stage renal disease, glycoprotein IIb/IIIa inhibitors, renal replacement therapy

Published Online, February 22, 2005. www.theannals.com, DOI 10.1345/aph.1E365


This article has been cited by other articles:


Home page
 CJASNHome page
M. Mrkobrada, H. Thiessen-Philbrook, R. B. Haynes, A. V. Iansavichus, F. Rehman, and A. X. Garg
Need for Quality Improvement in Renal Systematic Reviews
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1102 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A S. Mathis and J. J Gugger
Percutaneous Coronary Intervention-Related Bleeding Risk Factors in Current Practice
Ann. Pharmacother., October 1, 2005; 39(10): 1627 - 1632.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.